Protocolo de diagnóstico y tratamiento de la valvulopatía aórtica

  1. Longás Tejero, M.A.
  2. Santa Cruz Hernández, J.
  3. Guerra Torres, X.E.
  4. Araoz Illanes, R.
  5. Díaz Carretero, L.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Any de publicació: 2017

Sèrie: 12

Número: 40

Pàgines: 2400-2407

Tipus: Article

DOI: 10.1016/J.MED.2017.09.006 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Medicine: Programa de Formación Médica Continuada Acreditado

Objectius de Desenvolupament Sostenible

Resum

Abstract Clinical evaluation, baseline ECG, and chest x-ray (Rx) are mandatory in the initial diagnostic evaluation. Transthoracic echocardiography (TTE) is the main tool for diagnosis and follow-up. Other diagnostic techniques are also useful. Patients with severe symptomatic aortic stenosis should be involved, especially with aortic valve replacement surgery, and if the surgical risk is high, transcatheter aortic valve implantation (TAVI) may be an adequate alternative. Asymptomatic individuals will only be involved according to several factors predictive of onset of symptoms and adverse events. clinical evaluation, baseline ECG, and simple chest x-ray are also mandatory in the initial diagnostic evaluation. The ETT is the main diagnostic and monitoring tool. Acute severe aortic insufficiency (AI) should undergo urgent surgery. In chronic severe AI, when symptoms and/or systolic dysfunction of the left ventricle appear, aortic valve surgery must be performed; The asymptomatic patients will be operated according to several factors regarding left ventricular systolic size and function. Sometimes aortic root and ascending aorta surgery must be performed irrespective of the severity of the AI.

Referències bibliogràfiques

  • Otto CM, Bonow RO. Valvular heart disease. 8ª ed., Mann DL, Zipes DP, Libby P, Borow RO, Baunwald E, et al editores. Philadelphia: Saunders Elsevier; 2008. p. 1625-712.
  • Tornos Mas P, Sitges Carreño M. Valvulopatías. Farreras-Rozman: Medicina Interna, 19ª ed. Barcelona: Elsevier España, S.L.U.; 2016. p. 508-13.
  • O’Gara PT, Loscalzo J. Valvulopatía aórtica. Harrison: Principios de Medicina Interna. 19th ed. México, D.F.: McGraw-Hill Interamericana; 2016. p. 1528-38.
  • Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disesase of the European Society of Cardiology (ESC) and the European Association for Cardio Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42:S1-S44.
  • Iung B, Barón G, Butchart EG, Delahaye F, Gohike-Bärwolf C, Levang OW. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231-43.
  • Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enríquez-Sarano M. Burden of valvular heart disease: a population based study. Lancet. 2006;368:1005-11.
  • Levy F, Laurent M, Monin J, Maillet JM, Pasquet A, Le Tourneau T. Aortic valve replacement for low flow / low gradient aortic stenosis, operative risk stratification and long-term outcome: a European multicenter study. J Am Coll Cardiol. 2008;51:1466-72.
  • Di Pasquale G, Coutsoumbas GV, Zagnoni S. Severe low gradient aortic stenosis, with preserved ventricular function: should it be treated? J Cardiovasc Med. 2017;18Suppl1:e105-e111.
  • Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121: 306-14.
Fuente de los datos: Dialnet